ERD 308
CAS: 2320561-35-9
Ref. 3D-VSD56135
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Información del producto
ERD 308 is a small molecule that inhibits the proteasome-mediated degradation of proteins by inhibiting the ubiquitin-proteasome pathway. ERD 308 binds to the receptor α, which is a component of the ubiquitin ligase complex, and blocks the formation of a ternary complex with ubiquitin and an E1 enzyme. This prevents protein degradation by inhibiting the ubiquitin-proteasome system. ERD 308 has shown anticancer activity in vitro and in vivo, as well as pharmacokinetic properties that are favorable for dosing in humans. The compound has been developed as a potential treatment for breast cancer and other cancers.
Propiedades químicas
Consulta técnica sobre: 3D-VSD56135 ERD 308
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
